Search results for "Markers"

showing 10 items of 3115 documents

Demonstration of P29, an oestrogen receptor-associated tumor marker, in human term placenta.

1991

A Mr29,000 serine phosphoprotein (P29) related to oestradiol receptor was studied in human term placenta with the use of a specific monoclonal antibody (D5). D5 was used with two different methods, immunohistochemistry and immunoradiometry. For immunohistochemistry, an indirect immunoperoxidase method was chosen to detect P29 in methacarn-fixed, wax-embedded sections. P29 was mostly confined to the syncytiotrophoblast surrounding placental villi, staining being positive in both cytoplasm and nuclei. The stroma of villi was negative. Content of P29 was uniformly high in crude placental cytosol, as measured by immunoradiometry assays. Specificity of D5 against P29 in placenta was tested by an…

medicine.drug_classPlacentaBiologyMonoclonal antibodySyncytiotrophoblastPregnancyPlacentamedicineBiomarkers TumorSerineHumansHeat-Shock ProteinsImmunoperoxidaseObstetrics and GynecologyAntibodies MonoclonalPhosphoproteinsMolecular biologyImmunohistochemistryStainingTrophoblastsmedicine.anatomical_structureReproductive MedicineReceptors EstrogenCytoplasmPhosphoproteinembryonic structuresImmunohistochemistryFemaleImmunoradiometric AssayDevelopmental BiologyPlacenta
researchProduct

Characterization of a multimeric polypeptide complex on the surface of thymus-derived cells in the Mexican axolotl.

1993

We previously raised a rabbit antiserum (L12) against a 38 kD polypeptide which is expressed on the surface of thymocytes and peripheral T cells of an Urodele Amphibian, the Mexican axolotl (Ambystoma mexicanum). Here we show that L12 antibodies immunoprecipitate several labelled molecules from surface iodinated axolotl spleen cells, including the 38 kD molecule, but also two polypeptides of 43 and 22 kD which are covalently linked to other elements. Another rabbit antiserum (L10) was raised against detergent-solubilized axolotl thymocyte membranes and shown to recognize the majority of thymocytes and about half of the splenocytes in immunofluorescence. In Western blotting, L10 antibodies r…

medicine.drug_classT-LymphocytesImmunologyBlotting WesternFluorescent Antibody TechniqueThymus GlandBiologyImmunofluorescenceMonoclonal antibodyAntigen-Antibody ReactionsMiceAxolotlAntibody SpecificitymedicineSplenocyteAnimalsAntiserumB-LymphocytesMice Inbred BALB Cmedicine.diagnostic_testAntibodies MonoclonalGeneral MedicineT lymphocytebiology.organism_classificationMolecular biologyAmbystoma mexicanumMolecular WeightThymocyteAntigens Surfacebiology.proteinElectrophoresis Polyacrylamide GelRabbitsAntibodyPeptidesBiomarkersSpleenScandinavian journal of immunology
researchProduct

Identification of markers for the selection of patients undergoing renal cell carcinoma-specific immunotherapy

2003

Renal cell carcinoma (RCC) represents the most common malignant tumor in the kidney and is resistant to conventional therapies. The diagnosis of RCC is often delayed leading to progression and metastatic spread of the disease. Thus, validated markers for the early detection of the disease as well as selection of patients undergoing specific therapy is urgently needed. Using treatment with the monoclonal antibody (mAb) G250 as a model, proteome-based strategies were implemented for the identification of markers which may allow the discrimination between responders and nonresponders prior to application of G250-mediated immunotherapy. Flow cytometry revealed G250 surface expression in approxi…

medicine.drug_classmedicine.medical_treatmentMonoclonal antibodyBiochemistryMass SpectrometryFlow cytometrySequence Analysis ProteinRenal cell carcinomaCell Line TumorBiomarkers TumormedicineCarcinomaHumansElectrophoresis Gel Two-DimensionalCarcinoma Renal CellMolecular Biologybiologymedicine.diagnostic_testAntibodies MonoclonalProteinsImmunotherapyFlow Cytometrymedicine.diseaseKidney NeoplasmsImmunologyProteomebiology.proteinCancer researchImmunohistochemistryImmunotherapyAntibodyPROTEOMICS
researchProduct

Multimodality imaging strategies for the assessment of aortic stenosis: Viewpoint of the heart valve clinic international database (HAVEC) group

2016

International audience; Aortic stenosis is the most frequent valvular heart disease. In aortic stenosis, therapeutic decision essentially depends on symptomatic status, stenosis severity, and status of left ventricular systolic function. Surgical aortic valve replacement or transcatheter aortic valve implantation is the sole effective therapy in symptomatic patients with severe aortic stenosis, whereas the management of asymptomatic patients remains controversial and is mainly based on individual risk stratification. Imaging is fundamental for the initial diagnostic work-up, follow-up, and selection of the optimal timing and type of intervention. The present review provides specific recomme…

medicine.medical_specialty030204 cardiovascular system & hematologyDoppler echocardiographyAsymptomaticMultimodal ImagingRisk Assessment03 medical and health sciences0302 clinical medicineAortic valve replacementInternal medicinemedicineHumansRadiology Nuclear Medicine and imaging030212 general & internal medicineHeart valvehumanaortic valve stenosis ◼ biomarkers ◼ echocardiography Doppler ◼ guideline ◼ prognosis ◼ standardsalgorithmmedicine.diagnostic_testbusiness.industrypractice guidelinevalvular heart diseaseAortic Valve Stenosismedicine.diseasebiological markerPrognosis3. Good healthStenosismedicine.anatomical_structureclassificationAortic valve stenosisPractice Guidelines as TopicCardiologycardiovascular system[SDV.IB]Life Sciences [q-bio]/BioengineeringRadiologymedicine.symptomCardiology and Cardiovascular MedicineRisk assessmentbusinessAlgorithmsBiomarkers
researchProduct

The effects of ezetimibe on LDL-cholesterol: quantitative or qualitative changes ?

2009

Ezetimibe represents the first of a new class of agents, the cholesterol absorption inhibitors, able to reduce low-density lipoproteins (LDL)-cholesterol by 15-25% from baseline in monotherapy and on top of statins and fibrates. To-date all the data regarding the efficacy of ezetimibe comes from the studies of its lipid-lowering power. Yet, recent findings from the ENHANCE study on atherosclerosis progression showed that the addition of ezetimibe to simvastatin in patients with heterozygous familial hypercholesterolemia did not affect the mean change in carotid intima-media thickness, although a significant reduction in LDL-cholesterol levels was present. Therefore, we cannot exclude that e…

medicine.medical_specialty10265 Clinic for Endocrinology and Diabetology610 Medicine & healthFamilial hypercholesterolemiaBioinformatics2705 Cardiology and Cardiovascular Medicinechemistry.chemical_compoundEzetimibePredictive Value of TestsInternal medicinemedicineAnimalsHumansProspective cohort studyCardiovascular risk Cholesterol LDL size Small dense LDLDyslipidemiasEzetimibe LDL-cholesterolCholesterolVascular diseasebusiness.industryAnticholesteremic AgentsHypertriglyceridemiaReproducibility of ResultsCholesterol LDLEzetimibemedicine.diseaseTreatment OutcomeEndocrinologychemistrySimvastatinAzetidinesDrug Therapy Combinationlipids (amino acids peptides and proteins)Hydroxymethylglutaryl-CoA Reductase InhibitorsCardiology and Cardiovascular MedicinebusinessBiomarkersDyslipidemiamedicine.drug
researchProduct

The differential effects of thiazolidindiones on atherogenic dyslipidemia in type 2 diabetes: what is the clinical significance?

2008

Diabetic dyslipidemia is typically characterized by an increase in plasma triglycerides, a decrease in high-density lipoprotein cholesterol and a concomitant increase in atherogenic small dense low-density lipoproteins. Thiazolidindiones are able to lower the levels of fasting glucose and glycated hemoglobin significantly by improving insulin sensitivity, as well as improving some aspects of diabetic dyslipidemia: total cholesterol, low-density lipoprotein cholesterol and high-density lipoprotein cholesterol tend to increase while triglycerides are generally decreased.This paper reviewed the effects of pioglitazone and rosiglitazone on atherogenic diabetic dyslipidemia, in particular on sma…

medicine.medical_specialty10265 Clinic for Endocrinology and Diabetology610 Medicine & healthType 2 diabetesRosiglitazonechemistry.chemical_compoundDiabetes mellitusInternal medicinemedicine2736 Pharmacology (medical)HumansHypoglycemic AgentsPharmacology (medical)Clinical significancecardiovascular risk dense low-density lipoprotein diabetes low-density lipoprotein size pioglitazone rosiglitazone smallTriglyceridesDyslipidemiasPharmacologyAtherogenic dyslipidemiaPioglitazonebusiness.industryThiazolidindionesAtherogenic dyslipidemiaGeneral Medicinemedicine.diseaseLipoproteins LDLEndocrinology3004 PharmacologychemistryDiabetes Mellitus Type 2lipids (amino acids peptides and proteins)ThiazolidinedionesGlycated hemoglobinbusinessRosiglitazoneLipoproteins HDLPioglitazoneBiomarkersmedicine.drugLipoprotein
researchProduct

State of the Art-High-Sensitivity Troponins in Acute Coronary Syndromes.

2020

In cases of suspected acute coronary syndrome (ACS), rapid and accurate diagnosis is essential to establish effective evidence-based medical treatment. Patients' history, clinical examination, 12-lead electrocardiogram, and cardiac biomarkers are cornerstones in initial management. Since high-sensitivity cardiac troponins were established, they have markedly expedited and revolutionized rule-in and rule-out pathways of patients with ACS and changed our everyday clinical practice. Thus, they have become an indispensable tool in daily routine in emergency units. This review focuses on historical and contemporary standards in laboratory biomarkers of myocardial injury and discusses their impli…

medicine.medical_specialtyAcute coronary syndromeCardiac biomarkersMyocardial InfarctionPhysical examinationContext (language use)030204 cardiovascular system & hematologySensitivity and SpecificityDiagnosis Differential03 medical and health sciences0302 clinical medicinemedicineHumans030212 general & internal medicineMyocardial infarctionAcute Coronary SyndromeIntensive care medicinebiologymedicine.diagnostic_testMedical treatmentbusiness.industryGeneral Medicinemedicine.diseaseTroponinTroponinbiology.proteinBiomarker (medicine)Cardiology and Cardiovascular MedicinebusinessBiomarkersCardiology clinics
researchProduct

Diagnostic and prognostic value of H-FABP in acute coronary syndrome: Still evidence to bring

2018

Abstract The assessment of chest pain patients presenting to the emergency area (EA) is still a clinical challenge, as the majority of patients are not diagnosed with acute coronary syndrome (ACS). New generation high sensitivity c-Tn (hs-cTn) assays have showed better performances compared to the standard c-Tn. However, hs-Tn still presents some limitations. Hence, novel, early biomarkers are needed in this setting. Among all, heart-type fatty acid binding protein (H-FABP) has been largely investigated. This article reviews the studies evaluating H-FABP performance in diagnosing acute myocardial infarction (AMI) and stratifying chest pain patients by risk. H-FABP optimal performances in AC…

medicine.medical_specialtyAcute coronary syndromeClinical BiochemistryPredictive Value of Test030204 cardiovascular system & hematologyChest painClinical biochemistryAMIChest pain03 medical and health sciences0302 clinical medicinePredictive Value of TestsRule-inInternal medicinemedicineAnimalsHumans030212 general & internal medicineMyocardial infarctionAcute Coronary SyndromeRule-outAnimalbusiness.industrySmall sampleBiomarkerGeneral MedicineACSmedicine.diseasePredictive value of testsRisk stratificationH-FABPBiomarker (medicine)medicine.symptomTroponin CbusinessFatty Acid Binding Protein 3BiomarkersHumanClinical Biochemistry
researchProduct

Up-and-Coming Markers: Myeloperoxidase, a Novel Biomarker Test for Heart Failure and Acute Coronary Syndrome Application?

2008

Myeloperoxidase (MPO) is a mammalian enzyme responsible for generation of hypochlorite. The advantage of myeloperoxidase for use as a biomarker in the setting of heart failure and acute coronary syndrome is the early increase of MPO concentration in response to the acute event. In the setting of heart failure the reported independency of coronary artery disease and general inflammation, as indicated by MPO concentration in comparison to other inflammatory markers or in subgroups of patients with ischemic and non-ischemic cardiomyopathy, has to be highlighted. In terms of ACS, inclusion of MPO into a multiple marker strategy might add to enhance diagnosis and therapy decision making. Therefo…

medicine.medical_specialtyAcute coronary syndromeanimal diseasesCardiomyopathyInflammationDiseaseEmergency NursingDiagnosis DifferentialCoronary artery diseaseInternal medicinemedicineHumansAcute Coronary SyndromePeroxidaseHeart Failurebiologybusiness.industrymedicine.diseaseMyeloperoxidaseHeart failurebiology.proteinCardiologyEmergency MedicineBiomarker (medicine)medicine.symptombusinessCardiology and Cardiovascular MedicineBiomarkersCongestive Heart Failure
researchProduct

Tachykinin-, calcitonin gene-related peptide-, and protein gene product 9.5-immunoreactive nerve fibers in alveolar walls of mammals.

1991

The presence and distribution of the presumed pan-neural marker protein gene product 9.5 (PGP)- and peptide-immunoreactive (ir) nerve fibers in alveolar walls of various species was investigated by light microscopic single and double staining immunohistochemistry. PGP-, tachykinin (TK)-, and calcitonin gene-related peptide (CRGP)-ir fibers were sparsely distributed in a similar pattern in alveolar walls of all species investigated. No vasoactive intestinal peptide-, peptide histidine isoleucine-, galanin-, and opioid-ir nerve fibers could be detected. PGP-ir fibers outnumbered those staining for TKs and CGRP. There was partial coexistence of PGP and TK as well as of TK and CRGP. PGP-, TK-, …

medicine.medical_specialtyAlveolar EpitheliumCalcitonin Gene-Related PeptideVasoactive intestinal peptideGuinea PigsCalcitonin gene-related peptideBiologyAlveolar cellsDogsNerve FibersSpecies SpecificityInternal medicineCricetinaeTachykininsmedicineAnimalsGalaninMammalsintegumentary systemMesocricetusGeneral NeuroscienceNeuropeptidesrespiratory systemMolecular biologyRatsPulmonary Alveolimedicine.anatomical_structureEndocrinologyCalcitoninPeripheral nervous systemCatsPulmonary alveolusUbiquitin ThiolesteraseBiomarkersNeuroscience letters
researchProduct